<p>MAIA Biotechnology, Inc.（NYSEAMERICAN:MAIA - 獲取免費報告）在 12 月份的空頭頭寸顯著增加。截至 12 月 15 日，空頭頭寸總計為 1,685,137 股，比 11 月 30 日的 687,986 股增加了 144.9%。目前，該股票的 6.7% 股份被賣空。根據平均每日交易量 1,479,960 股，當前的覆蓋天數比率為 1.1 天。</p>
<p>獲取 <strong>MAIA Biotechnology</strong> 警報：</p>
<h2>MAIA Biotechnology 的內部買賣</h2>
<p>在相關消息中，董事 Ngar Yee Louie 於 12 月 22 日星期一購買了 81,699 股 MAIA Biotechnology 股票，交易的平均成本為每股 1.22 美元，總價值為 99,672.78 美元。購買完成後，該董事持有公司 1,248,888 股股票，價值為 1,523,643.36 美元。這代表其持股增加了 7.00%。該交易在證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，董事 Stan Smith 於 12 月 22 日星期一購買了 57,189 股公司的股票，平均成本為每股 1.22 美元，總交易額為 69,770.58 美元。購買完成後，該董事直接持有公司 1,421,478 股，價值約為 1,734,203.16 美元。這筆交易代表其持股增加了 4.19%。有關此次購買的更多細節可在官方 SEC 披露中找到。過去 90 天內，內部人士共購買了 368,352 股公司股票，價值為 427,192 美元。內部人士持有公司 32.32% 的股份。</p>
<h2>對 MAIA Biotechnology 的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近買賣了該股票的股份。Centerpoint Advisory Group 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 28,000 美元。Geode Capital Management LLC 在第二季度將其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前持有 222,183 股公司股票，價值為 400,000 美元，此前在該期間內又購買了 7,746 股。Centric Wealth Management 在第二季度將其在 MAIA Biotechnology 的股份增加了 740.2%。Centric Wealth Management 目前持有 573,398 股公司股票，價值為 1,032,000 美元，此前在該期間內又購買了 505,150 股。Marshall Wace LLP 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 29,000 美元。最後，Jane Street Group LLC 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 52,000 美元。目前，5.65% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>MAIA Biotechnology 股票上漲 6.1%</h2>
<p>在週五的交易中，NYSEAMERICAN MAIA 的股票上漲了 0.09 美元，達到 1.57 美元。該公司的交易量為 761,956 股，而其平均交易量為 977,358 股。該股票的市值為 5814 萬美元，市盈率為-2.15。MAIA Biotechnology 的 12 個月低點為 0.87 美元，12 個月高點為 2.74 美元。該公司的 50 日移動平均線為 1.22 美元，200 日移動平均線為 1.50 美元。</p>
<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）最後一次發佈季度財報是在 11 月 7 日星期五。該公司報告本季度每股收益為（0.27 美元），低於市場共識預期的（0.19 美元）0.08 美元。分析師預計 MAIA Biotechnology 在當前年度的每股收益將為-1.3。</p>
<h2>關於 MAIA Biotechnology</h2>
<p>（獲取免費報告）</p>
<p>MAIA Biotechnology, Inc 是一家臨牀階段的生物製藥公司，開發一種專有平台，用於單克隆抗體與診斷和治療放射性同位素的特異性結合。通過利用精確放射化學，該公司旨在增強基於抗體的成像劑和靶向放射治療的安全性和有效性。其方法旨在通過 PET 成像提供高對比度的腫瘤可視化，並在腫瘤學適應症中實現集中細胞毒性。</p>
<p>該公司的產品管線包括多個抗體 - 放射示蹤劑候選藥物，經過優化以檢測不同的腫瘤生物標誌物，臨牀前數據表明其靶向特異性和藥代動力學優於傳統方法。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MAIA Biotechnology</li>
<li>華盛頓為戰爭做準備</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MAIA Biotechnology 嗎？</h2>
<p>在你考慮 MAIA Biotechnology 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MAIA Biotechnology 並不在名單上。</p>
<p>雖然 MAIA Biotechnology 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

MAIA

<p>MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) 在 12 月份的空頭頭寸增加了 144.9%，總計達到 1,685,137 股。目前，該公司的 6.7% 股份被做空，空頭頭寸比率為 1.1 天。內部人士購入了大量股份，董事們進行了顯著的增持。該股票上漲了 6.1%，達到 1.57 美元，市值為 5814 萬美元。MAIA Biotechnology 是一家臨牀階段的生物製藥公司，專注於單克隆抗體和放射治療藥物</p>

<p>MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,685,137 shares, an increase of 144.9% from the November 30th total of 687,986 shares. Currently, 6.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Currently, 6.7% of the shares of the stock are sold short.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc.（NYSEAMERICAN:MAIA - 獲取免費報告）在 12 月份的空頭頭寸顯著增加。截至 12 月 15 日，空頭頭寸總計為 1,685,137 股，比 11 月 30 日的 687,986 股增加了 144.9%。目前，該股票的 6.7% 股份被賣空。根據平均每日交易量 1,479,960 股，當前的覆蓋天數比率為 1.1 天。</p>
</div><p>Get <strong>MAIA Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>MAIA Biotechnology</strong> 警報：</p>
</div><h2>Insider Buying and Selling at MAIA Biotechnology</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 的內部買賣</h2>
</div><p>In related news, Director Ngar Yee Louie acquired 81,699 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The shares were purchased at an average cost of $1.22 per share, with a total value of $99,672.78. Following the completion of the purchase, the director owned 1,248,888 shares of the company's stock, valued at $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Stan Smith purchased 57,189 shares of the firm's stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $69,770.58. Following the completion of the purchase, the director directly owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 368,352 shares of company stock valued at $427,192 over the last ninety days. Insiders own 32.32% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Ngar Yee Louie 於 12 月 22 日星期一購買了 81,699 股 MAIA Biotechnology 股票，交易的平均成本為每股 1.22 美元，總價值為 99,672.78 美元。購買完成後，該董事持有公司 1,248,888 股股票，價值為 1,523,643.36 美元。這代表其持股增加了 7.00%。該交易在證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，董事 Stan Smith 於 12 月 22 日星期一購買了 57,189 股公司的股票，平均成本為每股 1.22 美元，總交易額為 69,770.58 美元。購買完成後，該董事直接持有公司 1,421,478 股，價值約為 1,734,203.16 美元。這筆交易代表其持股增加了 4.19%。有關此次購買的更多細節可在官方 SEC 披露中找到。過去 90 天內，內部人士共購買了 368,352 股公司股票，價值為 427,192 美元。內部人士持有公司 32.32% 的股份。</p>
</div><h2>Hedge Funds Weigh In On MAIA Biotechnology</h2>
<div class="lb-trans"><h2>對 MAIA Biotechnology 的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Centerpoint Advisory Group purchased a new stake in MAIA Biotechnology in the second quarter worth about $28,000. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Finally, Jane Street Group LLC bought a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買賣了該股票的股份。Centerpoint Advisory Group 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 28,000 美元。Geode Capital Management LLC 在第二季度將其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前持有 222,183 股公司股票，價值為 400,000 美元，此前在該期間內又購買了 7,746 股。Centric Wealth Management 在第二季度將其在 MAIA Biotechnology 的股份增加了 740.2%。Centric Wealth Management 目前持有 573,398 股公司股票，價值為 1,032,000 美元，此前在該期間內又購買了 505,150 股。Marshall Wace LLP 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 29,000 美元。最後，Jane Street Group LLC 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為 52,000 美元。目前，5.65% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>MAIA Biotechnology Stock Up 6.1%</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 股票上漲 6.1%</h2>
</div><p>Shares of NYSEAMERICAN MAIA traded up $0.09 during trading on Friday, reaching $1.57. The company had a trading volume of 761,956 shares, compared to its average volume of 977,358. The stock has a market cap of $58.14 million and a PE ratio of -2.15. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $2.74. The business's 50-day moving average is $1.22 and its 200 day moving average is $1.50.</p>
<div class="lb-trans"><p>在週五的交易中，NYSEAMERICAN MAIA 的股票上漲了 0.09 美元，達到 1.57 美元。該公司的交易量為 761,956 股，而其平均交易量為 977,358 股。該股票的市值為 5814 萬美元，市盈率為-2.15。MAIA Biotechnology 的 12 個月低點為 0.87 美元，12 個月高點為 2.74 美元。該公司的 50 日移動平均線為 1.22 美元，200 日移動平均線為 1.50 美元。</p>
</div><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, analysts anticipate that MAIA Biotechnology will post -1.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）最後一次發佈季度財報是在 11 月 7 日星期五。該公司報告本季度每股收益為（0.27 美元），低於市場共識預期的（0.19 美元）0.08 美元。分析師預計 MAIA Biotechnology 在當前年度的每股收益將為-1.3。</p>
</div><h2>About MAIA Biotechnology</h2>
<div class="lb-trans"><h2>關於 MAIA Biotechnology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc 是一家臨牀階段的生物製藥公司，開發一種專有平台，用於單克隆抗體與診斷和治療放射性同位素的特異性結合。通過利用精確放射化學，該公司旨在增強基於抗體的成像劑和靶向放射治療的安全性和有效性。其方法旨在通過 PET 成像提供高對比度的腫瘤可視化，並在腫瘤學適應症中實現集中細胞毒性。</p>
</div><p>The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個抗體 - 放射示蹤劑候選藥物，經過優化以檢測不同的腫瘤生物標誌物，臨牀前數據表明其靶向特異性和藥代動力學優於傳統方法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than MAIA Biotechnology</li>
<li>Washington prepares for war</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MAIA Biotechnology</li>
<li>華盛頓為戰爭做準備</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MAIA Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MAIA Biotechnology 嗎？</h2>
</div><p>Before you consider MAIA Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MAIA Biotechnology 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MAIA Biotechnology 並不在名單上。</p>
</div><p>While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MAIA Biotechnology 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

MAIA Biotech 公司（NYSEAMERICAN:MAIA）在 12 月份的空頭頭寸增加了 144.9%